<SEC-DOCUMENT>0001104659-19-040466.txt : 20190716
<SEC-HEADER>0001104659-19-040466.hdr.sgml : 20190716
<ACCEPTANCE-DATETIME>20190716085447
ACCESSION NUMBER:		0001104659-19-040466
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190716
DATE AS OF CHANGE:		20190716

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-231777
		FILM NUMBER:		19956253

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>a19-3729_14fwp.htm
<DESCRIPTION>FWP
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuer Free Writing Prospectus dated July&nbsp;16, 2019</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed Pursuant to Rule&nbsp;433</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Relating to the Preliminary Prospectus dated July&nbsp;9, 2019 and</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registration Statement No.&nbsp;333-231777</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="329" height="96" src="g372914bci001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">This free writing prospectus relates to the U.S. initial public offering of American Depositary Shares (&#147;ADSs&#148;) of Genmab A/S (the &#147;Company&#148;), each representing one-tenth of one of the Company&#146;s ordinary shares. This free writing prospectus updates and supplements the information in the preliminary prospectus dated July&nbsp;9, 2019 (the &#147;Preliminary Prospectus&#148;) that was included in Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;F-1 (the &#147;Registration Statement&#148;) relating to this offering </font>of the Company&#146;s ADSs and should be read together with the Preliminary Prospectus.&#160; On July&nbsp;16, 2019, the Company filed Amendment No.&nbsp;2 to the Registration Statement (&#147;Amendment No.&nbsp;2&#148;), which Amendment No.&nbsp;2 includes an update to the Preliminary Prospectus (the &#147;Updated Preliminary Prospectus&#148;).&#160; Amendment No.&nbsp;2, including the Updated Preliminary Prospectus, may be accessed through the following link:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1434265/000104746919004195/a2239257zf-1a.htm">https://www.sec.gov/Archives/edgar/data/1434265/000104746919004195/a2239257zf-1a.htm</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Updated Preliminary Prospectus adds the following additional disclosure in the &#147;Recent Developments&#148; section of the Prospectus Summary on page&nbsp;12 of the Preliminary Prospectus:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent Developments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Entry into a DuoBody License Agreement with BliNK Biomedical</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On July&nbsp;12, 2019, we entered into an agreement with BliNK Biomedical for an exclusive commercial license to certain antibodies targeting CD47 for potential development and commercialization into novel bispecific therapeutics created via our proprietary DuoBody technology.&#160; Under the terms of the agreement, we will pay BliNK Biomedical an upfront fee of $2.25 million. BliNK Biomedical is also eligible to receive up to approximately $200.0 million in development, regulatory and commercial milestone payments for each product, as well as tiered royalties on net sales.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Submission of BLA to the FDA for SubQ Formulation of Daratumumab</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On July&nbsp;12, 2019, we announced that Janssen had submitted a Biologics License Application, or BLA, to the FDA for the use of the subQ formulation of daratumumab in MM indications where the IV formulation of daratumumab is currently approved. The submission is based on data from the Phase III COLUMBA study and preliminary non-public data from the ongoing Phase II PLEIADES study.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Net Sales of DARZALEX for the Second Quarter of 2019</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On July&nbsp;16, 2019, we announced net sales of DARZALEX for the second quarter of 2019, as reported by Johnson&nbsp;&amp; Johnson. Worldwide net sales of DARZALEX were $774 million in the second quarter of 2019 compared to $511 million in the second quarter of 2018, an increase of approximately 51%. The 2019 second quarter net sales were $369 million in the United States and $405 million in the rest of the world.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Johnson &amp; Johnson reported worldwide operational DARZALEX sales growth (excluding impact of foreign currency movements) between the two second quarter periods in 2018 and 2019, respectively, of approximately 57%. According to Johnson &amp; Johnson, sales in the second quarter of 2019 included a one-time adjustment outside the United States related to the completion of pricing and reimbursement discussions in certain European countries, which positively impacted this worldwide operational growth by 16 percentage points.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Company has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (the &#147;SEC&#148;) for the offering to which this communication relates.&#160; Before you invest, you should</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109764\19-3729-14\task9426777\3729-14-bc.htm',USER='109764',CD='Jul 16 17:59 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering.&#160; You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.&#160; Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it from: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email:&#160; dg.prospectus_requests@baml.com; Morgan Stanley&nbsp;&amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone: 1-877-821-7388, or by email: Prospectus_Department@Jefferies.com.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109764\19-3729-14\task9426777\3729-14-bc.htm',USER='109764',CD='Jul 16 17:59 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g372914bci001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g372914bci001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !@ 4D# 2(  A$! Q$!_\0
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MO;D^QQ_2O.;*QN-1N5@M8R[L>3CA?<GM7J-C:)8V,-M'RL2!<^OO0!/1110
M44V65(8FDE=41!EF8X %</J_Q%"2-%I,"N <>=+G!^B_XU48N6QC6Q%.BKS9
MW5%>9KXF\5S#S(DF*?[%ID?RJ>R^(6HVLWEZE;)*H^]A3&X_#I5^RD<JS*C?
M5->J/1:*I:5JUKK-F+FS<LF=I!&"I]"*NUDU8[XR4E=;!1110,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *B>Y@BD5))HT=CA59@"3Z
M5+7D6I1C3_&4HCX\J\#+[#<#_6KA#F.7%8EX=)VO=GKM%%%0=04444 %%%%
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M\0?^1E;_ *X)_6O4*\O^(7_(RM_UP3^M*C\1>:?P/F>B:39P6.F00VL2QQ[
M<#N2.2?4U'X@ /A[4 ?^?=__ $$U:M/^/.#_ *YK_*JNO_\ (OZA_P!>[_\
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(&+G56LM3_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
